We are early-stage with in-vitro proof of concept, no filed IP and no product on the market. This page says exactly what stage we are at and what the money buys.
A billion-dollar phytogenic category is growing at about 6% a year, with antimicrobial replacement already a leading application13. Regulation is also reducing routine antibiotic use in key export markets10.
Livestock antibiotic use is still projected to rise almost 30% by 20402, while AMR action is modelled to return US$28 for every US$1 invested6.
Green Antibiotics combines reproducible in-vitro leads with a twelve-month plan to filed IP, live-bird evidence and first revenue.
Indicative allocation. Final figures are in the investor pack.
Prior-art work and priority patent filings before further disclosure.
MIC/MBC, resistance, mechanism, safety and independent verification.
One controlled broiler trial designed to EFSA data standards.
CMO batches, potency assay, stability and controlled sourcing.
Classification advice for Bangladesh, UK and EU pathways.
Add animal-health regulatory and commercial execution capability.
Every early-stage investment carries risk. These are the specific ones here.
Agar activity may not reproduce in a live bird; the broiler study is the first gate.
The combinations stay unprotected until priority patent applications are filed.
Classification sets dossier scope, cost and timeline differently in each market.
Botanical potency must be controlled across harvests, suppliers and extraction batches.
Large incumbents hold the distribution; our differentiation has to be stronger evidence.
Phytogenics may lose efficacy under heavy challenge; cocktails must close the gap.12
Listing risks is easy. What matters to an investor is whether the plan retires them in a defined order, at a defined cost, with people who have done it before. Every mitigation below maps to a funded, dated deliverable in the twelve-month plan.
Run the live-bird study early; published work already supports this compound class in poultry.18
File priority patent applications before any further disclosure, publication or partner discussion.
Confirm classification early and run the fast regional route beside the EFSA dossier.
Control botanical variability through potency specifications and a formal stability programme.17
Compete on named-pathogen, resistant-isolate evidence that the large brands do not publish.
Multi-compound synergy is supported by published poultry work and our own screening.19
The round buys four re-rating milestones: filed IP, MIC data, resistance testing and one controlled poultry study.
Bangladesh operations provide a lower-cost base in the highest-burden AMR region1, while the UK company holds IP and the international regulatory pathway.
Avix has already moved T-Booster from laboratory concept through a completed 260-volunteer human study, manufacturing coordination and commercial preparation.
Dr David Brown adds senior discovery experience, Viagra co-invention, Relpax contribution and the published resistance-breaker concept5.
Grand View Research. Phytogenic Feed Additives Market Size, Share & Trends Analysis Report by Animal, Application, Distribution Channel and Region, Segment Forecasts 2025–2030. Market estimated at USD 1,047.9m (2024), forecast USD 1,484.7m (2030), 6.04% CAGR; poultry segment USD 492.6m (2024). grandviewresearch.com
European Union. Regulation (EU) 2019/6 on veterinary medicinal products, and Regulation (EC) 1831/2003 on additives for use in animal nutrition, under which EFSA evaluates feed additives prior to authorisation. eur-lex.europa.eu
Acosta A, Tirado M V, Cheng L, et al. The future of antibiotic use in livestock. Nature Communications, 16, 2025. doi:10.1038/s41467-025-56825-7
World Organisation for Animal Health (WOAH) and partners. EcoAMR series: Health and Economic Impacts of Antimicrobial Resistance in Humans and Food-Producing Animals, 2024. woah.org
Cardinal K M, Kipper M, Andretta I, Ribeiro A M L. Can phytogenic additives improve the performance of broilers and replace growth-promoting antibiotics? A meta-analytic approach. Canadian Journal of Animal Science, 2022. doi:10.1139/cjas-2021-0058
Shaji S, Selvaraj R K, Shanmugasundaram R, et al. Exploring the effects of phenolic compounds and essential oils in poultry: a sustainable strategy to combat Salmonella biofilm infections. Poultry Science, 2025. Reviews broad-spectrum activity, multi-target mechanism, and in-vivo reductions of Salmonella and Campylobacter of up to 50% in two weeks. doi:10.1016/j.psj.2025.105982
Alves-Silva J M, Zuzarte M, Girão H, Salgueiro L, et al. Reviews on the antimicrobial efficacy, volatility, instability and concentration-dependent toxicity of essential-oil compounds in animal production, including microencapsulation as a mitigation strategy. Antibiotics, 14(6):552, 2025. mdpi.com/2079-6382/14/6/552
Peñalver-Soler R, et al. Antimicrobial activity of Origanum vulgare L. and Salvia rosmarinus essential oil combinations against Escherichia coli and Salmonella Typhimurium isolated from poultry. Processes, 13(9):2856, 2025. Checkerboard synergy across five pH levels; strongest synergy at pH ≤ 5.5. doi:10.3390/pr13092856
GBD 2021 Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. The Lancet, 404(10459):1199–1226, 2024. doi:10.1016/S0140-6736(24)01867-1
Brown D. Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void? Nature Reviews Drug Discovery, 14:821–832, 2015. doi:10.1038/nrd4675 — authored by Green Antibiotics co-developer Dr David Brown.